Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877546 | 0.92 | NAMPT (0.45) | NAMPTHSD11B1LIPEMGLLKMT2A | |
| SCHEMBL2885164 | 0.84 | OPRL1 (0.48) | NAMPTHSD11B1MGLLKMT2A | |
| SCHEMBL2883181 | 0.80 | HPGD (0.39) | NAMPTHSD11B1LIPEMGLLKMT2A | |
| SCHEMBL2882732 | 0.80 | OPRL1 (0.48) | NAMPTHSD11B1LIPEMGLL | |
| SCHEMBL6493038 | 0.78 | BACE1 (0.46) | NAMPTHSD11B1 | |
| SCHEMBL2877543 | 0.76 | OPRL1 (0.48) | NAMPTHSD11B1MGLLKMT2A | |
| SCHEMBL6493917 | 0.75 | RAB9A (0.46) | NAMPT | |
| SCHEMBL2883246 | 0.73 | KMT2A (0.45) | NAMPTKMT2A | |
| SCHEMBL6501571 | 0.72 | BACE1 (0.49) | NAMPTHSD11B1 | |
| SCHEMBL6490446 | 0.72 | BACE1 (0.41) | LIPEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | NAMPT 1461/4885HSD11B1 1480/4885LIPE 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.